Gene · 2235
FECH: ferrochelatase
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. FECH: ferrochelatase. Genes, record 2235. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/2235
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P22830 | Ferrochelatase, mitochondrial | 423 | 25 | Ensembl, GeneID, HGNC |
Source UniProt
Patents49
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| EP 4705273 A2 | 2026-03-11 | 503 | P22830 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 46185 | P22830 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 2010 | P22830 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 2010 | P22830 | Espacenet |
| JP 2025081326 A | 2025-05-27 | 41 | P22830 | Espacenet |
| JP 2025013347 A | 2025-01-24 | 151 | P22830 | Espacenet |
| JP 2025013347 A | 2025-01-24 | 503 | P22830 | Espacenet |
| US 12201675 B2 | 2025-01-21 | 151 | P22830 | Espacenet |
| JP 2025003953 A | 2025-01-14 | 150 | P22830 | Espacenet |
| EP 4406585 A2 | 2024-07-31 | 151 | P22830 | Espacenet |
1 to 10 of 49
See all 49 patentsDrugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants1,110
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | FECH papers | Newest fiscal year |
|---|---|---|---|
| U54DK110858 | Center for Iron & Heme Disorders at the University of Utah | 15 | 2025 |
| ZIAHD008814 | Mammalian iron-sulfur cluster biogenesis | 13 | 2025 |
| R01EY025641 | Ferrochelatase as a mediator of ocular angiogenesis | 10 | 2025 |
| ZIAHD001602 | Regulation Of Intracellular Iron Metabolism | 10 | 2025 |
| P30DK034987 | Center for Gastrointestinal Biology and Disease | 8 | 2025 |
| R01DK074797 | Inter-organ signaling in heme metabolism and organismal homeostasis. | 6 | 2025 |
| P30CA023108 | Cancer Center Support Grant | 5 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 4 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 4 | 2025 |
| R35GM131701 | Mitochondrial Fidelity and Homeostasis | 4 | 2025 |
1 to 10 of 1,110Source NIH's project files
See all 1,110 nih grantsPapers1,987
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| A transferrin receptor-targeted liposome for iron metabolism regulation-augmented photodynamic therapy in glioblastoma. | Bioact Mater | 2027 | 42780992 | PubTator, text mining | PubMed |
| Griseofulvin as a dual-action agent against glioblastoma: anti-tumor effect and enhancement of 5-ALA photodynamic diagnosis in stem-like cells. | Cancer Treat Res Commun | 2026 | 42710153 | PubTator, text mining | PubMed |
| Acute on chronic liver failure in erythropoietic protoporphyria: A case report and review of the literature. | Hepatol Forum | 2026 | 42602091 | PubTator, text mining | PubMed |
| FECH, a novel metabolic target influencing CAR T-cell phenotype and function. | Biomark Res | 2026 | 42587334 | PubTator, text mining | PubMed |
| Design, synthesis, and evaluation of novel 5-aminolevulinic acid and 3-hydroxypyridinone conjugates for enhanced photodynamic therapy in triple-negative breast cancer. | Bioorg Med Chem Lett | 2026 | 42586492 | PubTator, text mining | PubMed |
| Results from the first clinical trial of bitopertin for steroid-relapsed/refractory Diamond-Blackfan anemia. | Blood Red Cells Iron | 2026 | 42583025 | PubTator, text mining | PubMed |
| Spatially resolved transcriptomic profiling of myelofibrosis spleen reveals compartment specific niche programs. | Exp Hematol Oncol | 2026 | 42547896 | PubTator, text mining | PubMed |
| Cascade Amplification of Photoimmunotherapy via Mitochondrial Dual-Ion Interference in a Bimetallic-Organic Framework. | Small | 2026 | 42535344 | PubTator, text mining | PubMed |
| AI-driven structure- and ligand-based discovery of novel Ferrochelatase inhibitors from heterocyclic libraries. | J Mol Graph Model | 2026 | 42520493 | PubTator, text mining | PubMed |
| Alectinib combined with 5-aminolevulinic acid-based photodynamic therapy promotes apoptosis in endometrial cancer cells by targeting ferrochelatase. | Front Oncol | 2026 | 42453882 | PubTator, text mining | PubMed |
1 to 10 of 1,987
See all 1,987 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/2235
GET https://conductscience.org/api/genes/v1/2235/patents?page=2